CD274 and neoplasm: PD-L1 tumor expression as a potential biomarker was explored in the present study for patients treated with the concurrent combination of ipilimumab and nivolumab (cohorts 1–3, 2A) and for those who received nivolumab monotherapy sequenced after prior ipilimumab (cohorts 6 and 7) (30).